Efficacy versus safety: The dilemma of using novel platelet inhibitors for the treatment of patients with ischemic stroke and coronary artery disease

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Coronary and cerebrovascular atherothrombosis are the leading cause of mortality and morbidity worldwide. Novel antiplatelet agents have been established for the management of patients with clinically evident coronary atherothrombosis and are increasingly used in these patients. These agents, however, have shown limited Efficacy in the prevention of cerebrovascular events and potential harm in patients with history of stroke or transient ischemic attack. Herein, the Efficacy and safety of two established antiplatelet agents in patients with stroke - aspirin and clopidogrel - are reviewed with a focus on the use and challenges related to novel antiplatelet agents - prasugrel, ticagrelor, and vorapaxar - in patients at risk for and with a history of stroke or transient ischemic attack.

Original languageEnglish
Pages (from-to)321-329
Number of pages9
JournalTherapeutics and Clinical Risk Management
Volume10
Issue number1
DOIs
Publication statusPublished - 2014

Fingerprint

Platelet Aggregation Inhibitors
stroke
Platelets
Coronary Artery Disease
clopidogrel
Stroke
Disease
Safety
Transient Ischemic Attack
history
Patient Harm
morbidity
Aspirin
Therapeutics
mortality
cause
event
Morbidity
management
Mortality

Keywords

  • Aspirin
  • Cerebrovascular disease
  • Clopidogrel
  • Coronary artery disease
  • Novel antiplatelet agents

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Medicine(all)
  • Pharmacology, Toxicology and Pharmaceutics(all)
  • Safety Research
  • Chemical Health and Safety

Cite this

@article{59e7aad6d299410784d51be6c62d5e6f,
title = "Efficacy versus safety: The dilemma of using novel platelet inhibitors for the treatment of patients with ischemic stroke and coronary artery disease",
abstract = "Coronary and cerebrovascular atherothrombosis are the leading cause of mortality and morbidity worldwide. Novel antiplatelet agents have been established for the management of patients with clinically evident coronary atherothrombosis and are increasingly used in these patients. These agents, however, have shown limited Efficacy in the prevention of cerebrovascular events and potential harm in patients with history of stroke or transient ischemic attack. Herein, the Efficacy and safety of two established antiplatelet agents in patients with stroke - aspirin and clopidogrel - are reviewed with a focus on the use and challenges related to novel antiplatelet agents - prasugrel, ticagrelor, and vorapaxar - in patients at risk for and with a history of stroke or transient ischemic attack.",
keywords = "Aspirin, Cerebrovascular disease, Clopidogrel, Coronary artery disease, Novel antiplatelet agents",
author = "Gianmarco Iannopollo and Rita Camporotondo and {De Ferrari}, {Gaetano M.} and Sergio Leonardi",
year = "2014",
doi = "10.2147/TCRM.S39216",
language = "English",
volume = "10",
pages = "321--329",
journal = "Therapeutics and Clinical Risk Management",
issn = "1176-6336",
publisher = "Dove Medical Press Ltd.",
number = "1",

}

TY - JOUR

T1 - Efficacy versus safety

T2 - The dilemma of using novel platelet inhibitors for the treatment of patients with ischemic stroke and coronary artery disease

AU - Iannopollo, Gianmarco

AU - Camporotondo, Rita

AU - De Ferrari, Gaetano M.

AU - Leonardi, Sergio

PY - 2014

Y1 - 2014

N2 - Coronary and cerebrovascular atherothrombosis are the leading cause of mortality and morbidity worldwide. Novel antiplatelet agents have been established for the management of patients with clinically evident coronary atherothrombosis and are increasingly used in these patients. These agents, however, have shown limited Efficacy in the prevention of cerebrovascular events and potential harm in patients with history of stroke or transient ischemic attack. Herein, the Efficacy and safety of two established antiplatelet agents in patients with stroke - aspirin and clopidogrel - are reviewed with a focus on the use and challenges related to novel antiplatelet agents - prasugrel, ticagrelor, and vorapaxar - in patients at risk for and with a history of stroke or transient ischemic attack.

AB - Coronary and cerebrovascular atherothrombosis are the leading cause of mortality and morbidity worldwide. Novel antiplatelet agents have been established for the management of patients with clinically evident coronary atherothrombosis and are increasingly used in these patients. These agents, however, have shown limited Efficacy in the prevention of cerebrovascular events and potential harm in patients with history of stroke or transient ischemic attack. Herein, the Efficacy and safety of two established antiplatelet agents in patients with stroke - aspirin and clopidogrel - are reviewed with a focus on the use and challenges related to novel antiplatelet agents - prasugrel, ticagrelor, and vorapaxar - in patients at risk for and with a history of stroke or transient ischemic attack.

KW - Aspirin

KW - Cerebrovascular disease

KW - Clopidogrel

KW - Coronary artery disease

KW - Novel antiplatelet agents

UR - http://www.scopus.com/inward/record.url?scp=84899829012&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84899829012&partnerID=8YFLogxK

U2 - 10.2147/TCRM.S39216

DO - 10.2147/TCRM.S39216

M3 - Article

AN - SCOPUS:84899829012

VL - 10

SP - 321

EP - 329

JO - Therapeutics and Clinical Risk Management

JF - Therapeutics and Clinical Risk Management

SN - 1176-6336

IS - 1

ER -